Pfizer (NYSE:PFE) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Pfizer (NYSE:PFE) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08, Zacks reports. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer updated its FY 2025 guidance to 3.000-3.150 EPS.

Pfizer Trading Down 0.3%

Shares of Pfizer stock traded down $0.08 during mid-day trading on Tuesday, hitting $24.58. The stock had a trading volume of 88,587,640 shares, compared to its average volume of 48,205,609. The firm has a 50-day moving average of $24.76 and a two-hundred day moving average of $24.31. The firm has a market cap of $139.76 billion, a P/E ratio of 13.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer has a 12-month low of $20.92 and a 12-month high of $28.00. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is 91.49%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently added to or reduced their stakes in PFE. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. Sei Investments Co. grew its position in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after buying an additional 631,523 shares during the last quarter. HUB Investment Partners LLC grew its position in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after buying an additional 31,896 shares during the last quarter. Finally, Vivaldi Capital Management LP grew its position in shares of Pfizer by 3.4% in the 2nd quarter. Vivaldi Capital Management LP now owns 14,438 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 472 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PFE. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.24.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.